About Savara Inc.
https://www.savarapharma.comSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CEO
Matthew Pauls
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-04-28 | Reverse | 1:70 |
| 2010-04-26 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:24.47M
Value:$146.83M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:17.6M
Value:$105.6M
VR ADVISER, LLC
Shares:12.68M
Value:$76.09M
Summary
Showing Top 3 of 141
About Savara Inc.
https://www.savarapharma.comSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $30.25M ▼ | $-29.56M ▲ | 0% | $-0.14 | $-29.49M ▲ |
| Q2-2025 | $0 | $31.05M ▲ | $-30.4M ▼ | 0% | $-0.14 ▼ | $-31.41M ▼ |
| Q1-2025 | $0 | $27.53M ▼ | $-26.64M ▲ | 0% | $-0.12 ▲ | $-27.62M ▲ |
| Q4-2024 | $0 | $31.1M ▲ | $-29.04M ▼ | 0% | $-0.14 ▼ | $-28.97M ▼ |
| Q3-2024 | $0 | $6.05M | $-24.25M | 0% | $-0.11 | $-26.32M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $124.39M ▼ | $140.92M ▼ | $46.54M ▲ | $94.39M ▼ |
| Q2-2025 | $146.44M ▼ | $163.76M ▼ | $43.28M ▲ | $120.48M ▼ |
| Q1-2025 | $172.5M ▼ | $189.32M ▼ | $41.47M ▲ | $147.85M ▼ |
| Q4-2024 | $196.33M ▼ | $212.88M ▼ | $41.43M ▲ | $171.45M ▼ |
| Q3-2024 | $219.44M | $238.82M | $39.47M | $199.35M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.56M ▲ | $-22.53M ▲ | $21.47M ▼ | $-23K ▲ | $-1.16M ▲ | $-22.53M ▲ |
| Q2-2025 | $-30.4M ▼ | $-26.26M ▲ | $24.33M ▼ | $-49K ▼ | $-2.12M ▼ | $-26.28M ▲ |
| Q1-2025 | $-26.64M ▲ | $-27.19M ▼ | $29.33M ▲ | $2.32M ▲ | $4.43M ▲ | $-27.19M ▼ |
| Q4-2024 | $-29.04M ▼ | $-23.28M ▼ | $17.89M ▲ | $-843K ▼ | $-6.3M ▼ | $-23.27M ▼ |
| Q3-2024 | $-24.25M | $-22.67M | $-98.17M | $118.32M | $-2.44M | $-22.67M |
CEO
Matthew Pauls
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-04-28 | Reverse | 1:70 |
| 2010-04-26 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:24.47M
Value:$146.83M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:17.6M
Value:$105.6M
VR ADVISER, LLC
Shares:12.68M
Value:$76.09M
Summary
Showing Top 3 of 141